Aurobindo Pharma receives USFDA approvals for 2 drugs

One is used for short-term treatment of active duodenal ulcer in adults and the other for the treatment of osteoporosis in postmenopausal women

Aurobindo Pharma on Thursday announced that it has received final approvals from the US Food and Drug Administration(USFDA) to manufacture and market two generic drugs, namely Ibandronate sodium Injection and Omeprazole delayed-release capsules of specific dosages.

Ibandronate Sodium Injection is a generic version of Boniva Injection of Hoffmann-La Roche, Inc., and is indicated for the treatment of osteoporosis in postmenopausal women.

Omeprazole Delayed-release capsules are a generic version of AstraZeneca Pharmaceuticals owned Prilosec drug and are indicated for short-term treatment of active duodenal ulcer in adults, according to a company press release.